Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

Liver Transplantation and Surgery

Volumn 5, Issue 6, 1999, Pages 520-525

  Yoshida, E M ^a   Erb, S R ^a   Partovi, N ^a   Scudamore, C H ^a   Chung, S W ^a   Frighetto, L ^a   Eggen, H J ^a   Steinbrecher, U P ^a  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOTHERAPY; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT OUTCOME;

EID: 0032704197     PISSN: 10743022     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500050602     Document Type: Article

References (29)

1. 1 Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 ; 329: 1842–1847. MEDLINE
2. 2 Belle SH, Beringer KC, Detre KM. Trends in liver transplantation in the United States. In: Terasaki PI, Cecka JM, (eds). Clinical transplants 1993. Los Angeles: UCLA Tissue Typing Laboratory, 1994 ; 19–35.
3. 3 Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996 ; 24: 1327–1333. MEDLINE
4. 4 McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996 ; 61: 1358–1364. MEDLINE
5. 5 Gugenheim J, Baldini E, Ouzan D, Mouiel J. Absence of initial viral replication and long‐term high‐dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant Proc 1997 ; 29: 517–518. MEDLINE
6. 6 Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg‐positive patients. Lancet 1991 ; 337: 813–815. MEDLINE
7. 7 Ilan Y, Eid A, Tur‐Kaspa R. Long‐term prevention of recurrent hepatitis B virus after liver transplantation. Isr J Med Sci 1995 ; 31: 469–473. MEDLINE
8. 8 So SKS, Esquivel CO, Imperial J, Garcia G, Concepcion W, Keeffe EB. Liver transplantation for HBeAg‐positive chronic HBV cirrhosis [abstract]. Hepatology 1996 ; 24: 581A.
9. 9 Lee SG, Lee YJ, Kwon TW, Park KM, Choi KM, Min PC, et al. Unlimited‐term passive immunoprophylaxis after liver transplantation in HBsAg‐positive patients. Transplant Proc 1996 ; 28: 1176–1177. MEDLINE
10. 10 Yoshida EM. Hepatitis B infection and liver transplantation. Can J Gastroenterol 1997 ; 11: 462–468. MEDLINE
11. 11 Lowell JA, Burgess S, Shenroy S, Peters M, Howard TK. Mercury poisoning associated with hepatitis B immunoglobulin [letter]. Lancet 1996 ; 347: 480. MEDLINE
12. 12 Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok ASF. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998 ; 27: 213–222. MEDLINE
13. 13 Protzer‐Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, zum Buschenfelde KHM, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high‐dose hepatitis B immune globulin after liver transplantation. Hepatology 1998 ; 27: 254–263. MEDLINE
14. 14 Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998 ; 28: 555–561. MEDLINE
15. 15 Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 ; 348: 1212–1215. MEDLINE
16. 16 Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fischer K, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996 ; 62: 1456–1462. MEDLINE
17. 17 Perillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, et al. Lamivudine for hepatitis B after liver transplantation (OLT) [abstract]. Hepatology 1996 ; 24: 182A.
18. 18 Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA–dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996 ; 24: 714–717. MEDLINE
19. 19 Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996 ; 24: 711–713. MEDLINE
20. 20 Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997 ; 349: 20–22. MEDLINE
21. 21 Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998 ; 27: 1670–1677. MEDLINE
22. 22 Gutfreund KS, Fischer KP, Bain VG, Ma M, Williams M, Yoshida E, et al. Genotypic succession of mutations of the HBV polymerase associated with lamivudine resistance in chronic hepatitis B and liver transplantation [abstract]. Hepatology 1998 ; 28: 487A.
23. 23 Yoshida EM, Ma MM, Davis JE, Fischer KP, Kneteman NM, Erb SR, et al. Post‐liver transplant allograft reinfection with a lamivudine‐resistant strain of hepatitis B virus: Long‐term follow‐up. Can J Gastroenterol 1998 ; 12: 125–129. MEDLINE
24. 24 Demetris AJ, Seaberg EC, Batts KP, Ferrell L, Ludwig J, Markin RS, et al. Reliability and predictive value of the NIDDK Liver Transplant Database nomenclature and grading system for cellular rejection of liver allografts. Hepatology 1995 ; 21: 408–416. MEDLINE
25. 25 Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine an hepatitis B immune globulin. Hepatology 1998 ; 28: 585–589. MEDLINE
26. 26 Burbach GJ, Bienzle U, Neuhaus R, Hopf U, Metzger WG, Pratschke J, Neuhaus P. Intravenous or intramuscular anti‐HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 1996 ; 63: 478–480.
27. 27 Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbers CD, Elias N, et al. Recurrence‐free long‐term survival after liver transplantation for hepatitis B using interferon‐alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997 ; 226: 356–368. MEDLINE
28. 28 Wong DHK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha‐interferon treatment in patients with hepatitis B e antigen‐positive chronic hepatitis B: A meta‐analysis. Ann Intern Med 1993 ; 119: 312–323. MEDLINE
29. 29 Lee WM. Hepatitis B virus infection. New Engl J Med 1997 ; 337: 1733–1745. MEDLINE